Previous 10 | Next 10 |
2023-05-09 15:39:56 ET Shares of Grifols (NASDAQ: GRFS) were up 11.1% on Tuesday afternoon, after being up as much as 13.1% earlier in the day. The pharmaceutical company, which makes plasma-derived medicines, released first-quarter earnings on Tuesday morning. The stock is down...
2023-05-09 07:59:14 ET Grifols S.A. press release ( NASDAQ: GRFS ): Q1 Adjusted EBITDA margin improves to 21.0% (excl. Biotest) and Adjusted EBITDA increases 19% to €299 million, driven by operational leverage and cost discipline. Adjusted EBITDA guidance ...
2023-05-08 13:08:20 ET Grifols S.A. ( NASDAQ: GRFS ) is scheduled to announce Q1 earnings results on Tuesday, May 9th, before market open. The consensus EPS Estimate is $0.08 and the consensus Revenue Estimate is $1.69B For further details see: Grifols S.A. Q1 20...
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023 PR Newswire BARCELONA, Spain , April 18, 2023 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and leading manufacturer of pl...
2023-04-12 10:50:20 ET Summary CSL Limited is one of the largest global biotechnology companies globally that specializes in the research, development, and manufacturing of plasma-based therapies, vaccines, and other pharmaceutical products. The combination of long-term revenue re...
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease PR Newswire CHICAGO , March 6, 2023 /PRNewswire/ -- Selagine, Inc., a spin-out company from the University...
Grifols, S.A. ( NASDAQ: GRFS ) traded lower Friday after Morgan Stanley downgraded the Spain-based operator of plasma collection centers, arguing that the company's FY22 results indicated a slower margin recovery. During the recent earnings call, Alfredo Arroyo, Chief Financial Office...
The following slide deck was published by Grifols, S.A. in conjunction with their 2022 Q4 earnings call. For further details see: Grifols, S.A. 2022 Q4 - Results - Earnings Call Presentation
Grifols, S.A. (GRFS) Q4 2022 Earnings Conference Call February 28, 2023 08:30 AM ET Company Participants Nuria Pascual - IR Thomas Glanzmann - Executive Chairman Victor Grifols Deu - Co-CEO Alfredo Arroyo - CFO Conference Call Participants Peter Verdult...
Grifols S.A. ( NASDAQ: GRFS ) is scheduled to announce FY earnings results on Tuesday, February 28th, before market open. The consensus EPS Estimate is $0.52 and the consensus Revenue Estimate is $6.25B Over the last 3 months, EPS estimates have seen 0 upward revisions and...
News, Short Squeeze, Breakout and More Instantly...
2024-06-12 02:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Grifols 2023 Annual Report on Form 20-F filed with the SEC PR Newswire BARCELONA, Spain , April 19, 2024 /PRNewswire/ -- Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived me...
2024-03-23 01:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...